Protein Kinase Signaling by Shiga Toxin Subunits
سال انتشار: 1401
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 152
فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_JMSI-12-1_010
تاریخ نمایه سازی: 28 تیر 1402
چکیده مقاله:
Background: Escherichia coli produces Shiga toxin (Stx), a pentamer composed of one A subunit
and four B subunits. The B subunit of Stx (StxB) mediated the attachment of the holotoxin to the
cell surface while the A subunit (StxA) has N-glycosidase activity, resulting in protein synthesis
and cell death inhibition. Stx-induced cytotoxicity and apoptosis have been observed in various cell
lines, although the signaling effectors are not precisely defined. Activated by protein kinases (PK),
the signaling pathway in human tumors plays an oncogenic role. Tumor proliferation, survival, and
metastasis are promoted by kinase receptors. In this regard, PK regulatory effects on the cellular
constituents of the tumor microenvironment can affect immunosuppressive purposes. Methods: In this
study, kinase inhibitors were used to evaluate the influence of Stx and its subunits on HeLa and Vero
cells. Selective inhibitors of protein kinase C (PKC), CaM kinase (calmodulin kinase), protein kinase
A (PKA), and protein kinase G (PKG) were used to compare the signaling activity of each subunit.
Results: The ribotoxic activity in the target cells will lead to rapid protein synthesis inhibition and
cell death in the mammalian host. The expression of Bcl۲ family members was also assessed. Protein
kinase signaling by Stx and its A and B subunits was induced by PKA, PKG, and PKC in HeLa cells.
CaM kinase induction was significant in Vero cells. StxB significantly induced the pro-apoptotic Bax
signaling factor in HeLa cells. Conclusion: The assessment of different signaling pathways utilized
by Stx and its subunits could help in a better understanding of various cell death responses. The use
of inhibitors can block cell damage and disease progression and create therapeutic compounds for
targeted cancer therapy. Inhibition of these pathways is the primary clinical goal.
کلیدواژه ها:
نویسندگان
Mana Oloomi
Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran
Neda Moazzezy
Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran
Saeid Bouzari
Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran